EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries

Niels Abildgaard, Pekka Anttila, Anders Waage, Katrine Hass Rubin, Sigurd Ørstavik, Nawal Bent-Ennakhil, François Gavini, Yuanjun Ma, Jonatan Freilich, Markus Hansson

European Journal of Cancer · 2024-04 · 201 · 113921

DOI: 10.1016/j.ejca.2024.113921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-04. Verfasst von Niels Abildgaard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Research Unit, Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of South…. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company, Takeda Pharmaceuticals International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: The Health outcomes and Understanding of MyelomA multi-National Study (HUMANS) was a large-scale, retrospective study conducted across Denmark, Finland and Sweden using linked data from national registries. We describe the characteristics, treatment patterns and clinical outcomes for patients with newly diagnosed multiple myeloma (NDMM) over 2010-2018. METHODS: Patients with NDMM who received MM-specific, first-line treatments, were categorised by treatment (autologous stem cell transplantation [ASCT] or a combination chemotherapy regimen based on bortezomib, lenalidomide or melphalan-prednisolone-thalidomide). RESULTS: 11,023 patients received treatment over 2010-2018. Time between diagnosis and treatment was shortest in Denmark (0.9 months), then Sweden (2.9 months) and Finland (4.6 months). Around one third of patients underwent ASCT. Lenalidomide-based regimens were prescribed to 23-28% of patients in Denmark and Finland, versus 12% in Sweden. Patients receiving lenalidomide had the longest wait for treatment, from 3.2 months (Denmark) to 12.1 months (Sweden). Treatment persistence was highest among patients receiving melphalan-prednisolone-thalidomide (7-8 months) in Finland and Sweden and lowest among those receiving bortezomib (3.5 months) in Finland. Overall survival (OS) was longest among patients with ASCT (7-10 years). Among patients receiving chemotherapy, OS (from diagnosis/treatment initiation), varied between cohorts. In a sensitivity analysis excluding patients with smouldering MM, OS decreased for all; for patients receiving bortezomib or lenalidomide, OS from diagnosis was 40-49 and 27-54 months, respectively. CONCLUSIONS: This population-based study of patients with NDMM receiving first-line MM-specific treatment, provides real-world data on treatment patterns and outcomes to complement data from randomised clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationHumansLenalidomideBortezomibThalidomideMelphalanFinlandRetrospective StudiesSwedenDexamethasoneTransplantation, AutologousAntineoplastic Combined Chemotherapy ProtocolsPrednisoloneRegistriesDenmark

Stichwörter der Autor:innen

BortezomibLenalidomideMelphalanMultiple myelomaNordic registriesOutcomesReal worldSurvivalTreatment patterns

Substanzen

LenalidomideBortezomibThalidomideMelphalanDexamethasonePrednisolone

Autor:innen und Institutionen

  • Hematology Research Unit, Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: niels.abildgaard@rsy…
  • Comprehensive Cancer Center, Department of Hematology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.
  • Department of Hematology, St Olav's University Hospital, Trondheim, Norway.
  • Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Takeda Pharmaceuticals International AG, Oslo, Norway.
  • Takeda Pharmaceuticals International AG, Zurich, Switzerland.

Förderung

  • Takeda Pharmaceutical Company
  • Takeda Pharmaceuticals International

Zitieren

APA

Abildgaard, N., Anttila, P., Waage, A., Rubin, K. H., Ørstavik, S., Bent-Ennakhil, N., Gavini, F., Ma, Y., Freilich, J., & Hansson, M. (2024). Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries. European Journal of Cancer, 201, 113921. https://doi.org/10.1016/j.ejca.2024.113921

Vancouver

Abildgaard N, Anttila P, Waage A, Rubin KH, Ørstavik S, Bent-Ennakhil N, et al. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries. European Journal of Cancer. 2024;201:113921. doi:10.1016/j.ejca.2024.113921

BibTeX
@article{Abildgaard2024,
  author = {Abildgaard, Niels and Anttila, Pekka and Waage, Anders and Rubin, Katrine Hass and Ørstavik, Sigurd and Bent-Ennakhil, Nawal and Gavini, François and Ma, Yuanjun and Freilich, Jonatan and Hansson, Markus},
  title = {Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {201},
  pages = {113921},
  doi = {10.1016/j.ejca.2024.113921}
}
Kostenlos starten →